Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma
- PMID: 23326166
- PMCID: PMC3542757
- DOI: 10.3748/wjg.v19.i1.78
Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma
Abstract
Aim: To identify factors associated with prognosis of hepatocellular carcinoma (HCC) after initial therapy.
Methods: A total of 377 HCC patients who were newly treated at Katsushika Medical Center, Japan from January 2000 to December 2009 and followed up for > 2 years, or died during follow-up, were enrolled. The factors related to survival were first analyzed in 377 patients with HCC tumor stage T1-T4 using multivariate Cox proportional hazards regression analysis. A similar analysis was performed in 282 patients with tumor stage T1-T3. Additionally, factors associated with the period between initial and subsequent therapy were examined in 144 patients who did not show local recurrence. Finally, 214 HCC stage T1-T3 patients who died during the observation period were classified into four groups according to their alcohol consumption and postprandial glucose levels, and differences in their causes of death were examined.
Results: On multivariate Cox proportional hazards regression analysis, the following were significantly associated with survival: underlying liver disease stage [non-cirrhosis/Child-Pugh A vs B/C, hazard ratio (HR): 0.603, 95% CI: 0.417-0.874, P = 0.0079], HCC stage (T1/T2 vs T3/T4, HR: 0.447, 95% CI: 0.347-0.576, P < 0.0001), and mean postprandial plasma glucose after initial therapy (< 200 vs ≥ 200 mg/dL, HR: 0.181, 95% CI: 0.067-0.488, P = 0.0008). In T1-T3 patients, uninterrupted alcohol consumption after initial therapy (no vs yes, HR: 0.641, 95% CI: 0.469-0.877, P = 0.0055) was significant in addition to underlying liver disease stage (non-cirrhosis/Child-Pugh A vs B/C, HR: 0649, 95% CI: 0.476-0.885, P = 0.0068), HCC stage (T1 vs T2/T3, HR: 0.788, 95% CI: 0.653-0.945, P = 0.0108), and mean postprandial plasma glucose after initial therapy (< 200 mg/dL vs ≥ 200 mg/dL, HR: 0.502, 95% CI: 0.337-0.747, P = 0.0005). In patients without local recurrence, time from initial to subsequent therapy for newly emerging HCC was significantly longer in the "postprandial glucose within 200 mg/dL group" than the "postprandial glucose > 200 mg/dL group" (log-rank test, P < 0.05), whereas there was no difference in the period between the "non-alcohol group" (patients who did not drink regularly or those who could reduce their daily consumption to < 20 g) and the "continuation group" (drinkers who continued to drink > 20 g daily). Of 214 T1-T3 patients who died during the observation period, death caused by other than HCC progression was significantly more frequent in "group AL" (patients in the continuation and postprandial glucose within 200 mg/dL groups) than "group N" (patients in the non-alcohol and postprandial glucose within 200 mg/dL groups) (P = 0.0016).
Conclusion: This study found that abstinence from habitual alcohol consumption and intensive care for diabetes mellitus were related to improved prognosis in HCC patients.
Keywords: Alcohol consumption; Diabetes mellitus; Hepatocellular carcinoma; Initial therapy; Local recurrence; Postprandial plasma glucose level; Prognosis; Survival.
Figures


Similar articles
-
Risk Factors for Hepatocellular Carcinoma Recurrence and Survival after Liver Transplantation in Patients with HCV-Related Cirrhosis.Biomed Res Int. 2020 Oct 17;2020:1487593. doi: 10.1155/2020/1487593. eCollection 2020. Biomed Res Int. 2020. PMID: 33134370 Free PMC article.
-
Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy.World J Gastroenterol. 2013 Jan 14;19(2):249-57. doi: 10.3748/wjg.v19.i2.249. World J Gastroenterol. 2013. PMID: 23345948 Free PMC article.
-
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.Clin Gastroenterol Hepatol. 2019 May;17(6):1183-1191.e7. doi: 10.1016/j.cgh.2018.10.038. Epub 2018 Oct 26. Clin Gastroenterol Hepatol. 2019. PMID: 30613002
-
Clinical value of circulating tumor cells for the diagnosis and prognosis of hepatocellular carcinoma (HCC): A systematic review and meta-analysis.Medicine (Baltimore). 2020 Oct 2;99(40):e22242. doi: 10.1097/MD.0000000000022242. Medicine (Baltimore). 2020. PMID: 33019399 Free PMC article.
-
Postprandial Plasma Glucose.Clin Diabetes. 2024 Nov 7;43(1):161-164. doi: 10.2337/cd24-0099. eCollection 2025 Winter. Clin Diabetes. 2024. PMID: 39829699 Review. No abstract available.
Cited by
-
Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality: A Systematic Review and Meta-Analysis.Am J Clin Oncol. 2018 Sep;41(9):874-881. doi: 10.1097/COC.0000000000000388. Am J Clin Oncol. 2018. PMID: 28537989 Free PMC article.
-
Occupational Class and Cancer Survival in Korean Men: Follow-Up Study of Nation-Wide Working Population.Int J Environ Res Public Health. 2020 Jan 1;17(1):303. doi: 10.3390/ijerph17010303. Int J Environ Res Public Health. 2020. PMID: 31906362 Free PMC article.
-
Hyperglycemia-Induced miR-467 Drives Tumor Inflammation and Growth in Breast Cancer.Cancers (Basel). 2021 Mar 16;13(6):1346. doi: 10.3390/cancers13061346. Cancers (Basel). 2021. PMID: 33809756 Free PMC article.
-
Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?World J Gastroenterol. 2014 Jul 28;20(28):9217-28. doi: 10.3748/wjg.v20.i28.9217. World J Gastroenterol. 2014. PMID: 25071314 Free PMC article. Review.
-
Postprandial Plasma Glucose between 4 and 7.9 h May Be a Potential Diagnostic Marker for Diabetes.Biomedicines. 2024 Jun 13;12(6):1313. doi: 10.3390/biomedicines12061313. Biomedicines. 2024. PMID: 38927521 Free PMC article.
References
-
- Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene. 2006;25:3771–3777. - PubMed
-
- Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993;18:47–53. - PubMed
-
- Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430. - PubMed
-
- Ikai I, Itai Y, Okita K, Omata M, Kojiro M, Kobayashi K, Nakanuma Y, Futagawa S, Makuuchi M, Yamaoka Y. Report of the 15th follow-up survey of primary liver cancer. Hepatol Res. 2004;28:21–29. - PubMed
-
- Noguchi K, Nakashima O, Nakashima Y, Shiota K, Nawata H, Kojiro M. Clinicopathologic study on hepatocellular carcinoma negative for hepatitis B surface antigen and antibody to hepatitis C virus. Int J Mol Med. 2000;6:661–665. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical